Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich…